Leerink Partnrs Has Negative Outlook for Insulet Q4 Earnings

Insulet Co. (NASDAQ:PODD) – Equities researchers at Leerink Partnrs lowered their Q4 2024 earnings estimates for shares of Insulet in a report issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now forecasts that the medical instruments supplier will post earnings per share of $0.97 for the quarter, down from their previous forecast of $0.99. The consensus estimate for Insulet’s current full-year earnings is $3.22 per share. Leerink Partnrs also issued estimates for Insulet’s Q2 2025 earnings at $0.87 EPS, Q3 2025 earnings at $1.14 EPS, Q4 2025 earnings at $1.20 EPS, FY2025 earnings at $3.89 EPS, FY2026 earnings at $5.21 EPS and FY2027 earnings at $6.49 EPS.

Other analysts have also recently issued reports about the company. Piper Sandler raised their target price on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Raymond James lifted their price objective on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. Barclays increased their target price on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Citigroup upped their price target on shares of Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. Finally, Morgan Stanley increased their price objective on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a report on Monday, November 11th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $266.58 on Tuesday. The firm’s 50 day moving average is $241.97 and its two-hundred day moving average is $211.65. The firm has a market capitalization of $18.70 billion, a P/E ratio of 45.65, a PEG ratio of 4.02 and a beta of 1.22. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet has a 52 week low of $160.19 and a 52 week high of $279.40.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PODD. Motley Fool Asset Management LLC lifted its position in shares of Insulet by 7.1% in the 1st quarter. Motley Fool Asset Management LLC now owns 1,397 shares of the medical instruments supplier’s stock valued at $239,000 after acquiring an additional 93 shares in the last quarter. Tidal Investments LLC boosted its position in shares of Insulet by 58.8% in the first quarter. Tidal Investments LLC now owns 4,064 shares of the medical instruments supplier’s stock worth $697,000 after buying an additional 1,504 shares during the period. iA Global Asset Management Inc. purchased a new position in shares of Insulet during the first quarter valued at $105,000. Plato Investment Management Ltd raised its position in Insulet by 1,574.0% during the first quarter. Plato Investment Management Ltd now owns 6,060 shares of the medical instruments supplier’s stock valued at $1,039,000 after buying an additional 5,698 shares during the period. Finally, Swedbank AB purchased a new stake in Insulet in the 1st quarter worth about $6,903,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.